About Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes.
Quality Assessment
Oramed Pharmaceuticals Inc. is a below-average quality healthcare company with a Compass Score of 21. Weak fundamentals or high volatility. More of a speculative position than a core holding.
Score Breakdown
The Compass Score is based on 6 quality factors identified by academic research.
Click any factor to see detailed metrics
Valuation Metrics
Click any metric for details
Wall Street View
Catalyst Signal
PlusRecent earnings beats and analyst-upgrade momentum. How it works
Analyst Track Record
Financial Health
PlusClick any metric for details
Growth Projections
PlusTechnical Overview
Click any metric for details
Similar High-Quality Stocks
Important Disclaimer
The Compass Score is for educational purposes only and does not constitute financial advice. Past performance does not guarantee future results. Always do your own research and consider consulting a financial advisor before making investment decisions.
Unlock Detailed Metrics
Upgrade to Plus to see the actual financial values behind each quality factor.
- See exact ROA, cash flow ratios, and more
- Unlimited stock views + smart search
- Export data to CSV
- Golden Stocks + analyst coverage
Cancel anytime